Hims & Hers Health (HIMS) is back in the spotlight after its Q4 2025 earnings per share beat, which contrasted with softer Q1 2026 revenue guidance and mounting regulatory and legal pressures.

Those mixed earnings and guidance headlines have landed on a stock that was already under pressure, with a 30 day share price return of 47.44% declines and a year to date share price return of 53.31% declines. The 1 year total shareholder return is a 62.26% loss, in contrast to a 50.72% gain over three years and 15.04% over five years. This suggests recent momentum has faded even though longer term holders are still ahead overall.

If Hims & Hers volatility has you looking beyond a single telehealth name, it could be a moment to broaden your search and check out 29 healthcare AI stocks as potential next ideas to research.

So with Hims & Hers shares sliding, guidance reset and fresh regulatory and legal pressure already on the table, is the current valuation overly harsh, or is the market simply recalibrating for more muted future growth?

Most Popular Narrative: 81.9% Undervalued

According to the most followed narrative on Hims & Hers Health, the gap between its fair value estimate of $86.09 and the last close at $15.60 is wide, and that difference rests on an aggressive long term platform story rather than short term sentiment.

Hims & Hers Health (HIMS) has been one of the most impressive growth stories in public markets, but recent developments have introduced material uncertainty in the medium term. While I remain confident in the long-term thesis, I’m becoming more cautious as regulatory tensions begin to affect execution.

Read the complete narrative. Read the complete narrative.

Want to see what kind of revenue growth, margin profile, and future earnings multiple are baked into that $86.09 figure? The narrative by BlackGoat leans on ambitious scaling assumptions, platform style economics, and a long runway in multiple healthcare verticals. The exact numbers and timing behind that 81.9% discount call are where the real story sits.

Result: Fair Value of $86.09 (UNDERVALUED)

However, that bullish setup still hinges on sensitive points, such as tighter scrutiny of GLP 1 practices and the impact of any further fallout with major pharma partners.

Next Steps

If this mix of optimism and concern feels familiar, do not sit on the sidelines.

Looking for more investment ideas?

If this story has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas that match the way you like to invest.

• Target value first and see which companies our screener flags as 54 high quality undervalued stocks based on strong fundamentals and pricing that may not fully reflect them.
• Prioritise resilience and check out 80 resilient stocks with low risk scores if you prefer businesses with steadier profiles and fewer red flags in their risk checks.
• Spot early stage potential by scanning 30 elite penny stocks with strong financials where smaller companies with room to grow might fit your next high conviction idea.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.